Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer [Phase 1, Phase 2]
This clinical trial update notes that Nanjing Leads Biolabs Co., Ltd. is recruiting for a Phase 1/2 study of LBL-024 as a monotherapy or in …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer [Phase 2]
A Phase 2 trial evaluating neoadjuvant SBRT with intratumoural pembrolizumab followed by neoadjuvant chemotherapy in breast cancer is curren…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Onvansertib + Paclitaxel In TNBC [Phase 1, Phase 2]
This document reports an ongoing Phase 1/2 clinical trial evaluating the combination of onvansertib with paclitaxel in patients with triple-…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer [NA]
Feasibility study evaluating a biobehavioral stress reduction intervention for patients with breast cancer, including triple-negative breast…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab [Phase 1]
Phase 1 trial update for ASTX660 in combination with pembrolizumab in advanced cancers, including cervical cancer and triple-negative breast…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating whether extended-dose interval immunotherapy provides similar or better efficacy and safety compared …
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating NT-I7 (efineptakin alfa) in combination with pembrolizumab in adults with advanced solid tumors has completed and…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage [EARLY_Phase 1]
A pilot Phase 1 study at Rutgers is evaluating circulating tumor DNA as a biomarker in early-stage triple-negative and HER2-positive breast …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer [Phase 2]
This clinical trial update describes a Phase 2 study of genomically guided radiation therapy for treating triple-negative breast cancer, cur…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Study of Screening Brain MRIs in Stage IV Breast Cancer
A clinical trial at H. Lee Moffitt Cancer Center is evaluating the use of screening brain MRIs in patients with Stage IV breast cancer, incl…
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies [Phase 1]
Phase 1 dose-escalation and expansion study of PRGN-3007 UltraCAR-T cells in patients with advanced hematologic and solid tumors has complet…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Tier Palliative Care For Patients With Advanced Heart Failure or Cancer [NA]
This clinical trial update describes a Mount Sinai–sponsored tiered palliative care study for patients with advanced heart failure or cancer…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating tiragolumab in combination with atezolizumab and chemotherapy for triple-negative breast cancer is currently acti…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer [Phase 1]
Phase 1 trial update for DC1 therapy (DecipHER) in early-stage triple-negative breast cancer and ER-low positive breast cancer. The study is…
-
CLINICAL_TRIALS withdrawal · 2026-02-04Clinical Trial Update: Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer [NA]
Withdrawn clinical trial evaluating a virtual mental health intervention for fear of progression in women with high-risk or stage III-IV gyn…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung [Phase 2]
A Phase 2 randomized trial evaluating stereotactic body radiation therapy (SBRT) in patients with oligoprogressive metastatic breast and lun…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) [NA]
A prospective biobanking study by Institut Curie (SCANDARE) aims to understand how tumor molecular alterations relate to the tumor microenvi…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) [Phase 2]
A Phase 2 neoadjuvant trial evaluating serplulimab plus weekly paclitaxel and carboplatin in triple-negative breast cancer; the study status…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]
Phase 1/2 study of novel anti-cancer agents in patients with metastatic triple-negative breast cancer; results have been posted on 2026-02-0…
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments [Phase 2]
A Phase 2 trial evaluating sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who have had at least two…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating sacituzumab govitecan at an alternative dose and schedule in advanced triple-negative breast cancer is…
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC [Phase 3]
Phase 3 clinical trial evaluating SBRT in combination with a PD-1 inhibitor and chemotherapy for early-stage triple-negative breast cancer; …
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC [Phase 2]
Phase 2 study of HB0025 in combination with nab-paclitaxel as first-line therapy for triple-negative breast cancer, currently enrolling by i…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy [Phase 2]
Phase 2 neoadjuvant trial for early triple-negative breast cancer evaluating a response-guided approach using Iparomlimab and Tuvonralimab i…
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating sacituzumab govitecan in combination with atropine to improve tolerability in advanced breast cancers, i…